Genetic Testing Will Contribute To Growth In Drug Spending, Medco Predicts
The growing prevalence of genetic testing as a clinical tool will drive increased drug spending and have a significant impact on medical practice, Medco predicts in its 2006 Drug Trend Report
You may also be interested in...
The move to personalized medicine will not put an end to the pharmaceutical blockbuster model, Pfizer Senior VP-Science & Technology Peter Corr said May 16
Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested
The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada